la Revue de Médecine Interne. 2005 Oct 5; [Epub ahead of print] [Link]
Glehen O, Cotte E, Brigand C, Arvieux C, Sayag-Beaujard AC, Gilly FN.
Service de chirurgie generale, thoracique et endocrinienne, centre hospitalo-universitaire Lyon-Sud, 69495 Pierre-Benite, cedex France; EA 3738, faculte de medecine Lyon-Sud, Oullins, France.
Purpose: Peritoneal carcinomatosis and particularly those from digestive origin has long been considered as an automatically terminal disease in abdominal cancer patients.
Current knowledge and key points: Over the past decade, new locoregional treatments combining cytoreductive surgery, peritonectomy procedures with perioperative intraperitoneal chemotherapy (with or without hyperthermia) have been developed by specialized teams. Because of its high but acceptable mortality and morbidity, this aggressive but comprehensive therapeutic strategy requires accurate and strict patient’s selection into multidisciplinary and specialized teams. It may allow prolonged survival and cure for patients with pseudomyxoma peritonei, peritoneal mesothelioma, carcinomatosis from colorectal or gastric cancer. Qualitative and quantitative prognostic indicators are needed to assess a patient’s eligibility, including tumor histopathology, assessment of carcinomatosis extent or completeness of cytoreduction which appears to be the most important.
Perspectives: Combination of cytoreductive surgery with perioperative intraperitoneal chemotherapy appears to be an adapted therapeutic approach for patients strictly selected, with peritoneal carcinomatosis. Phase III studies are now needed for the validation and the evaluation of the type of intraperitoneal chemotherapy.